Introduction
============

Spirometry, the most frequently performed pulmonary function test (other than arterial blood gas study), plays an important role in diagnosing the presence and type of lung 'abnormality' and classifying its severity. It plays a key role in medical surveillance examinations for occupational lung diseases, in determining whether to institute preventive or therapeutic measures, and in granting benefits to individuals with lung impairment. Observed spirometric data are compared to reference data and are expressed as percent predicted values, based on age, gender, height and race ([@b2-copd-2-361]). The purpose of such a comparison is to determine 'normality' vs. 'abnormality' and in cases of 'abnormality', to determine its 'severity'. The reference value is calculated from a regression equation derived from a population of 'normal' subjects.

In the United States, a variety of reference standards are available for commercial use by pulmonary function testing laboratories. The American Thoracic Society and European Respiratory Society (ATS-ERS) have recently recommended the use of the third National Health and Nutrition Examination Survey (NHANES III) reference standard for the interpretation of spirometry in the United States ([@b21-copd-2-361]). This reference standard provides ethnically appropriate equations for Caucasian Americans, African Americans, and Mexican Americans, thus obviating the need for less suitable and arbitrary race/ethnic adjustment factors ([@b11-copd-2-361]). Over time, the NHANES III reference will likely become the standard in most pulmonary function testing laboratories around the country.

The purpose of this study was to characterize the well-known 'problem' of the changed interpretation of the presence and severity of a spirometric 'abnormality' in Caucasian Americans as a consequence of the change from other commonly used reference standards ([@b16-copd-2-361]; [@b12-copd-2-361]) to NHANES III by pulmonary function testing laboratories in the United States. Although the concept of disagreement between the various reference standards is well-known ([@b17-copd-2-361]; [@b7-copd-2-361]; [@b5-copd-2-361]; [@b11-copd-2-361]; [@b25-copd-2-361]), the objective of this study was to better quantify these differences with respect to spirometric interpretation.

Methods
=======

This is a cross-sectional study of 1,106 non-Hispanic Caucasian American adult subjects who were referred by their physicians for spirometric testing at a single pulmonary function laboratory at a teaching hospital in Central Illinois. The spirometries were performed by trained technicians, using standard equipment and techniques that met the [@b3-copd-2-361], [@b4-copd-2-361]). This study was limited to non-Hispanic Caucasian American subjects to minimize the effect of race and ethnicity on the study results. The subjects were weighed and height measured, in indoor clothing without shoes, using a calibrated scale and stadiometer respectively. Age was recorded to the nearest birthday. The research using human subjects was conducted in accordance with the Helsinki Declaration and was approved by the local Institutional Review Board.

A spirometry was considered 'abnormal' if it met either of the following obstructive or restrictive criteria. Obstructive spirometric 'abnormality' was defined as the ratio of the forced expiratory volume in one second to the forced vital capacity (FEV~1~/FVC) below the lower limit of normal for the reference standard. Restrictive spirometric 'abnormality' was defined as the FEV~1~/FVC ratio greater than or equal to the lower limit of normal and FVC below the lower limit of normal for the reference standard. The lower limit of normal for FEV~1~, FVC, and FEV~1~/FVC ratio were directly obtained from the literature for the NHANES III reference standard ([@b11-copd-2-361]). The lower limit of normal for the above parameters for the Morris ([@b17-copd-2-361]); Crapo ([@b7-copd-2-361]), and Knudson ([@b12-copd-2-361]) reference standards were calculated by using the following equation -- Lower limit of normal for the parameter = Predicted value of the parameter −1.645\*Standard error of the estimate of the parameter.

In order to further classify the severity of spirometric 'abnormality', regression equations from the NHANES III were first used, as described above, to define the population with a spirometric 'abnormality' ([@b11-copd-2-361]). Subsequently, the severity of spirometric 'abnormality' was calculated in this population for each of the various commonly used reference standards, based upon the percentage predicted FEV~1~ values. The reference standards used for this part of the study included those by Morris ([@b16-copd-2-361]; [@b17-copd-2-361], [@b18-copd-2-361]); Kory ([@b14-copd-2-361]); Crapo ([@b7-copd-2-361]); Knudson ([@b13-copd-2-361]); Knudson ([@b12-copd-2-361]); and NHANES III ([@b11-copd-2-361]). The use of percent predicted FEV~1~ value in classifying severity of obstructive or restrictive spirometric 'abnormality' (as outlined in Table [1](#t1-copd-2-361){ref-type="table"}) has been recommended in the recent ATS/ERS guidelines ([@b21-copd-2-361]). The use of a 'gold standard' reference standard (ie, NHANES III) in initially defining the presence of 'abnormality' allowed the use of a uniform population for this comparison.

Statistical analysis
--------------------

A weighted Kappa (κ) statistic was used to evaluate the level of agreement between the various reference standards in classifying the presence and severity of obstructive and restrictive spirometric 'abnormalities'. κ is a measure of agreement compared to chance agreement. The κ statistic was interpreted using the guidelines suggested by Altman in Table [2](#t2-copd-2-361){ref-type="table"} ([@b1-copd-2-361]). A generalized McNemar test was performed to evaluate for the presence of bias. A p value of \< 0.05 was considered to be significant.

Results
=======

The 1,106 non-Hispanic Caucasian American adult subjects studied were mixed rural and urban residents, smokers and non-smokers, diseased and healthy individuals, who under-went a spirometry for diagnostic purposes at a Midwestern teaching hospital. They included 706 women (63.87%) and 400 men (36.13%), ranging in age from 18 to 91 years, with a mean age of 49.19 years. The body mass index ranged from 10.22 to 62.76 kg/m2, with a mean body mass index of 27.41 ± 7.04 kg/m2. The 1,106 subjects included 644 with no 'abnormalities', 228 with restrictive, and 234 with obstructive 'abnormalities', as per the NHANES III reference values and lower limits of the normal range.

For comparing the presence of any spirometric 'abnormality', the level of agreement between the other reference standards and NHANES III varied from poor (κ of 0.13 between Crapo and NHANES III) to moderate (κ of 0.44 between [@b12-copd-2-361] and NHANES III, and 0.46 between Morris and NHANES III), as shown in Table [3](#t3-copd-2-361){ref-type="table"}. As compared to the NHANES III reference standard, the use of Morris et al (1983) reference standards was associated with an increased likelihood of interpreting the presence of any 'abnormality' and of obstructive 'abnormality' and reduced likelihood of interpreting the presence of a restrictive spirometric 'abnormality'.

In order to compare the classification of severity of lung impairment, the study evaluated 234 subjects with obstructive and 228 subjects with restrictive spirometric 'abnormalities', as defined by the NHANES III reference standard ([@b11-copd-2-361]). For classifying the severity of obstructive spirometric 'abnormalities', the level of agreement between the other reference standards and NHANES III varied from good (κ of 0.77 between Morris and NHANES III) to very good (κ of 0.91 between Crapo and NHANES III), as shown in Table [4](#t4-copd-2-361){ref-type="table"}. As compared to the NHANES III reference standard, the 'abnormality' was classified as less severe by the [@b16-copd-2-361] reference standards (p \< 0.001), usually less severe by the [@b12-copd-2-361] reference standards (although the trend for the latter was not significant, p = 0.06), and of similar severity by the Crapo reference standard (p = 0.77).

A similar approach was used for comparing the severity classification of restrictive spirometric 'abnormalities' between the various reference standards. The level of agreement between the other reference standards and NHANES III for classifying the severity of restrictive 'abnormality' varied from good (κ of 0.61 between Morris and NHANES III) to very good (κ of 0.87 between Crapo and NHANES III), as shown in Table [5](#t5-copd-2-361){ref-type="table"}. As compared to the NHANES III reference standard, the 'abnormality' was classified as less severe by the [@b16-copd-2-361] reference standards (p \< 0.001), usually less severe by the [@b12-copd-2-361] reference standard (although the trend for the latter was not significant, p = 0.06), and of similar severity by the Crapo reference standard (p = 1.0). For both obstructive and restrictive spirometric 'abnormalities', the percent disagreement with NHANES III on severity rating was the largest when Morris was the original reference standard used.

Discussion
==========

As a US-based pulmonary function laboratory considers switching to the ATS/ERS-recommended NHANES III reference standard, it needs to be aware that the presence and severity of spirometric 'abnormality' may be classified differently, causing confusion in the minds of both the patients and their treating physicians. The extent of disagreement with the NHANES III-based interpretation will vary, depending upon the reference standard originally used. Particular caution must be exercised if the Crapo reference standard was originally used to classify the presence of spirometric 'abnormality' or if the Morris reference standard was originally used to classify the severity of spirometric 'abnormality' ([@b17-copd-2-361]). This is particularly important since Morris and Crapo were the two most common reference standards previously used in the United States, based upon a study in 1990 ([@b9-copd-2-361]).

The 1991 ATS guidelines had recommended that the best way for each pulmonary function testing laboratory was to perform its own reference value study. The advantage of this approach was that it minimized biological variation (since the reference population was a sample of the population served by the laboratory), and analytical imprecision (since the same instruments, technical staff, and procedures were used for both the reference population and patients). However, the disadvantage of this approach was that it required a relatively large number of 'healthy' subjects to be tested by each laboratory ([@b21-copd-2-361]). Unfortunately, reference standards in a laboratory were often chosen because they were available in the pulmonary function test equipment of the laboratory, rather than because they had been analyzed and found to be the best for the local population. The 2005 ATS/ERS guidelines therefore, recognized that the previous recommendation ([@b2-copd-2-361]) that each laboratory perform its own reference value study was impractical for most laboratories ([@b21-copd-2-361]).

However, the previous recommendation (1991) also resulted in a variety of reference standards being used by the laboratories in the United States, posing a challenge for the geographically mobile American population ([@b23-copd-2-361]) and their providers. For example, a 1990 questionnaire survey of 139 adult respiratory disease training programs in the United States and Canada ([@b9-copd-2-361]) revealed the use of the Morris reference standard by 47% ([@b16-copd-2-361]; [@b17-copd-2-361], [@b18-copd-2-361]), the Crapo standard by 19% ([@b7-copd-2-361]), the [@b12-copd-2-361] standard by 17% ([@b12-copd-2-361]), the Kory standard by 5%, ([@b14-copd-2-361]) and other reference standards (such as the [@b13-copd-2-361] standard; [@b13-copd-2-361]) by 10% of the programs. Subsequently, data obtained from the NHANES III study, that included a random sampling of 7,429 healthy subjects from 81 counties across the US ([@b11-copd-2-361]), was used to develop regression equations as well. Characteristics of these various reference standards are summarized in Table [6](#t6-copd-2-361){ref-type="table"}.

The 2005 ATS/ERS guidelines also recommended the use of the NHANES III reference standard in the United States, although it suggested that other standards may be used if there were valid reasons for that choice ([@b21-copd-2-361]). The advantages of the NHANES III standard include the large size and random selection of the population studied, across a large age range, with nearly equal numbers of Caucasian-Americans, African-Americans, and Mexican-Americans, rigorous quality control measures, and statistically sound coefficients for the lower limit of normal values. Further, the universal use of a nation-wide equation is likely to decrease the inter-laboratory variability in interpreting spirometric values, a challenge for the geographically mobile American population ([@b23-copd-2-361]).

Use of alternative reference standards may however, be valid in certain clinical settings that may currently 'mandate' the use of a specific standard. For instance, the [@b13-copd-2-361] Standard ([@b13-copd-2-361]) is currently used by cotton and other industries for spirometry testing done for medical surveillance of workers in the occupational setting ([@b19-copd-2-361], [@b20-copd-2-361]). The disagreement in classification of severity of spirometric 'abnormality' using NHANES III instead of the [@b13-copd-2-361] Standard ([@b13-copd-2-361]) in the occupational setting may range as high as 21.5%, as shown in Table [5](#t5-copd-2-361){ref-type="table"}. Similarly, the Black Lung Benefits Program for coal miners ([@b8-copd-2-361]) currently employs only the [@b12-copd-2-361] standards ([@b12-copd-2-361]) and the American Medical Guides to the Evaluation of Permanent Impairment (American Medical Association 2001) currently uses only the prediction equations by Crapo et al ([@b7-copd-2-361]). Although it is likely that some of these programs may switch to the NHANES III reference standard in the future, health care providers need to be mindful that its current use may result in significant disagreements regarding the presence and severity of spirometric 'abnormality' under such clinical settings.

The reported disagreement between NHANES III and various other reference standards in interpretation of spirometry in this study may relate to either biological variation or analytical imprecision. Biological variation may have been introduced by the fact that the population studied by Morris ([@b17-copd-2-361]) were relatively unexposed to significant urban air pollution or cigarette smoke, were at low altitude, and were largely volunteers from the Church of Jesus Christ of the Latter-day Saints (Mormon) of diverse northern and middle European background but possibly not representative of white Europeans or Americans as a whole. The only other population involving the Mormon religious sect was studied by [@b7-copd-2-361] but at a higher altitude of 1,400 ms. and in urban areas. Thus, ancestral background, altitude, and rural residence may contribute to biological variation that may potentially cause lack of agreement with the NHANES III reference population. Further, prediction equations based on cross-sectional analyses may not be predictive of longitudinal changes ([@b10-copd-2-361]). The possibility of secular trends in improving lung function among the US birth cohorts may be a reason why the best reference standards of yesterday may differ with the more recent NHANES III reference standard.

Further, analytical imprecision may result from a difference in the technique used. Morris calculated FVC and FEV~1~ using the Kory technique ([@b14-copd-2-361]) rather than the back extrapolation technique now recommended by the ATS/ERS ([@b15-copd-2-361]). The average FEV~1~ calculated with the back extrapolation technique exceeds that calculated with the Kory technique by 179 ml ([@b24-copd-2-361]). This may explain why Morris classifies a lower level of severity for both obstructive and restrictive spirometric 'abnormalities', when compared to the NHANES III reference standard. Further, [@b7-copd-2-361] showed that their study produced predicted values for FVC and FEV~1~ that were almost identical to those predicted by Morris et al when the data from the Morris study were modified to be compatible with the back extrapolation technique recommended by the ATS/ERS ([@b15-copd-2-361]). Crapo et al used the single curve with the largest sum of FVC and FEV~1~ and not the ATS recommended largest values from separate curves, if needed. This may result in a reduction of about 50 ml in the predicted value of FVC by the Crapo reference standard. Knudson et al used an older pneumotachograph spirometer for his reference standards that may have terminated the maneuver prematurely, resulting in lower mean FVC values ([@b12-copd-2-361], [@b13-copd-2-361]). The study with the highest predicted FVC and FEV~1~ values, NHANES III, had extensive quality control and subjects performed at least 5 FVC maneuvers -- likely explaining the slightly larger mean FVC and FEV~1~ values ([@b11-copd-2-361]). Further, if a laboratory uses the NHANES III reference values and does not emphasize deep inhalations with sufficient expiratory times, a larger number of their patients may falsely appear to have a restrictive lung disease pattern.

The strength of this study is that it better quantifies the differences with respect to spirometric interpretation, between the NHANES III and other reference standards used in the United States. The results of this study are therefore, of practical significance to an American treating physician. This study however, has several limitations. The NHANES III reference standard was used to define 'abnormality' in this study, instead of an extensive clinical work-up of symptoms, pulmonary function, and radiographic testing. The study results depend upon the prevalence of disease in the study population, and will therefore change if the population studied differs in disease prevalence. Further, the study does not use the vital capacity measure instead of FVC, as is recommended by the 2005 ATS/ERS guidelines ([@b21-copd-2-361]).

Summary
=======

The change of spirometric reference standard to NHANES III, as is recommended by the ATS/ERS guidelines ([@b21-copd-2-361]), by pulmonary function testing laboratories across the United States, may result in varying interpretations of the presence and level of severity of 'abnormality' ([@b22-copd-2-361]). This difference, in turn, may result in differences in clinical follow-up and prognosis, different conclusions in longitudinal studies, and influence eligibility criteria for clinical interventions and for research studies. Particular caution must be exercised if the Crapo reference standard ([@b7-copd-2-361]) was originally used to rate the presence of spirometric 'abnormalities' or if the Morris reference standard was originally used to rate its' 'severity' ([@b17-copd-2-361]).
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###### 

Classification of severity of any spirometric 'abnormality', based upon the forced expiratory volume in one second (FEV~1~) ([@b21-copd-2-361])

  **Percent predicted FEV~1~**   **Degree of severity**
  ------------------------------ ------------------------
  ≥70                            Mild
  60--69                         Moderate
  50--59                         Moderately severe
  35--49                         Severe
  \<35                           Very severe

###### 

Guidelines for interpreting Kappa (κ) statistic ([@b1-copd-2-361])

  **Kappa** (κ) **statistic**   **Level of agreement**
  ----------------------------- ------------------------
  0.81--1.00                    Very good agreement
  0.61--0.80                    Good agreement
  0.41--0.60                    Moderate agreement
  0.21--0.40                    Fair agreement
  ≤0.20                         Poor agreement

###### 

Effect of change of reference standard to NHANES III ([@b11-copd-2-361]) on the presence of any spirometric 'abnormality' (n = 1,106, of which 644 had no 'abnormalities', 228 had restrictive and 234 had obstructive 'abnormalities' as per the NHANES III standard)

  **Reference equation**   **Percent disagreement**   **Weighted Kappa [\*](#tfn1-copd-2-361){ref-type="table-fn"}**   **Generalized McNemar's test**   **Comment on comparison with NHANES III reference standard**
  ------------------------ -------------------------- ---------------------------------------------------------------- -------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@b17-copd-2-361]        33.88%                     0.46 (0.41, 0.50)                                                p \< 0.001                       Morris more likely to show any 'abnormality', or obstructive 'abnormality'; and less likely to show restrictive 'abnormality'. Morris is also more likely to interpret restrictive 'abnormality' as normal or obstructive
  [@b7-copd-2-361]         61.70%                     0.13 (0.10, 0.15)                                                p \< 0.001                       Crapo more likely to show any 'abnormality', or obstructive 'abnormality'; and less likely to show restrictive 'abnormality'. Crapo is also more likely to interpret restrictive 'abnormality' as normal or obstructive
  [@b12-copd-2-361]        35.14%                     0.44 (0.40, 0.49)                                                p \< 0.001                       Knudson more likely to show any 'abnormality', or obstructive 'abnormality'; and less likely to show restrictive 'abnormality'. Knudson is also more likely to interpret restrictive 'abnormality' as normal or obstructive

Numbers in parenthesis reflect 95% confidence intervals

###### 

Effect of change of reference standard to NHANES III ([@b11-copd-2-361]) on the classification of severity of obstructive spirometric 'abnormality' (n = 234), using percent predicted FEV~1~

  **Reference equation**   **Percent disagreement**   **Weighted Kappa [\*](#tfn2-copd-2-361){ref-type="table-fn"}**   **Generalized McNemar's test**   **Comment on comparison with NHANES III reference standard**
  ------------------------ -------------------------- ---------------------------------------------------------------- -------------------------------- ----------------------------------------------------------------------------------------------------------
  [@b17-copd-2-361]        28.20                      0.77 (0.72, 0.82)                                                p \< 0.001                       Morris classifies a lower level of severity
  [@b14-copd-2-361]        17.94                      0.85 (0.81, 0.90)                                                p \< 0.001                       Kory classifies a lower level of severity
  [@b7-copd-2-361]         11.96                      0.91 (0.88, 0.94)                                                p = 0.77                         Crapo classifies a similar level of severity
  [@b13-copd-2-361]        18.80                      0.85 (0.80, 0.89)                                                p \< 0.001                       Knudson usually classifies a lower level of severity
  [@b12-copd-2-361]        14.53                      0.88 (0.85, 0.92)                                                p = 0.06                         Knudson tends to classify a lower level of severity, although the trend is not statistically significant

Numbers in parenthesis reflect 95% confidence intervals

###### 

Effect of change of reference standard to NHANES III ([@b11-copd-2-361]) on the classification of severity of restrictive spirometric 'abnormality', using percent predicted FVC (n = 228)

  **Reference equation**   **Percent disagreement**   **Weighted Kappa**   **Generalized McNemar's test**   **Comment on comparison with NHANES III reference standard**
  ------------------------ -------------------------- -------------------- -------------------------------- ----------------------------------------------------------------------------------------------------------
  [@b17-copd-2-361]        32.46                      0.61 (0.54, 0.69)    p \< 0.001                       Morris classifies a lower level of severity
  [@b14-copd-2-361]        21.49                      0.75 (0.69, 0.81)    p \< 0.001                       Kory classifies a lower level of severity
  [@b7-copd-2-361]         12.28                      0.87 (0.82, 0.92)    p = 1.00                         Crapo classifies a similar level of severity
  [@b13-copd-2-361]        22.37                      0.74 (0.67, 0.80)    p \< 0.001                       Knudson usually classifies a lower level of severity
  [@b12-copd-2-361]        14.49                      0.84 (0.78, 0.89)    p = 0.06                         Knudson tends to classify a lower level of severity, although the trend is not statistically significant

Numbers in parenthesis reflect 95% confidence intervals

###### 

Summary of characteristics of various reference standards

  **Reference equation and date of publication**   **Type of Instrument and ability to meet ATS specifications**                      **Time zero technique**   **Population characteristic**                                                                                           **Method of screening**
  ------------------------------------------------ ---------------------------------------------------------------------------------- ------------------------- ----------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------
  NHANES III-1999 [@b11-copd-2-361]                Dry rolling-seal spirometer with a digital shaft encoder, met ATS specifications   Back extrapolation        Nonsmoker Caucasians, African Americans, and Mexican Americans                                                          History
  [@b17-copd-2-361]                                Stead-Wells, met ATS specifications                                                Kory technique            988 rural non-Hispanic white nonsmokers, largely of Mormon sect, in an area \<150 ms. altitude, free of air pollution   History
  [@b14-copd-2-361]                                Collins 13.5 L metal bell, met ATS specifications                                  Kory technique            Hospital employees, patients, medical students, doctors in urban locale                                                 History, physical examination, chest radiographs, and electrocardiogram
  [@b7-copd-2-361]                                 Collins 13.5 L metal bell, met ATS specifications                                  Back extrapolation        Urban, non-Hispanic white nonsmokers, largely of Mormon sect, at an altitude of 1,400 ms.                               History, physicalexamination, andchest radiographs
  [@b13-copd-2-361]                                Pneumotachygraph, met ATS specifications                                           Back extrapolation        746 nonsmoker, non-Mexican white population, without pregnant women, at 730 ms. altitude                                History
  [@b12-copd-2-361]                                Pneumotachygraph, met ATS specifications                                           Back extrapolation        697 nonsmoking non-Mexican white population                                                                             History
